Sosei's Drug Re-Profiling Strategy: A Three-Way Street

By going after Big Pharma's late-stage cast-offs, biotechs that want to be drug developers can lop years off the development time compared to de novo pharmaceutical discovery. The in-licensed compounds have already met, at the least, the druggability hurdle; their intellectual property is nailed down, they've passed the ADMET tests, and they're scalable. This strategy promises to maximize the assets of large company drug originators and give to younger, smaller companies access to compounds for in-licensing. However, the companies that could benefit the most from such an in-licensing strategy, the platform biotechs, often don't. The companies need compounds to move from platforms to product models, but pharma just doesn't see what these partners, based around a single technology and without a presence in the marketplace, can do for them. Now Japan's Sosei Co. Ltd. has come up with a new drug re-profiling strategy that makes licensing a three-way street; for itself, for platform biotechs and for pharmaceutical firms.

By going after Big Pharma's late-stage cast-offs, biotechs that want to be drug developers can lop years off the development time compared to de novo pharmaceutical discovery. The in-licensed compounds have already met, at the least, the druggability hurdle; their intellectual property is nailed down, they've passed the ADMET tests, and they're scalable. This strategy promises to maximize the assets of large company drug originators and give younger, smaller companies access to compounds for in-licensing. However, out-licensers still face many hurdles, which prevent them from being able to engage in the practice. (See In-Licensing: Still a Difficult Model, START-UP, November 2003 Also see "In-Licensing: Still a Difficult Model" - Scrip, 1 November, 2003..)

On the out-licensing side, Big Pharma has widespread fear of letting go, partly because the primary goal of licensing executives...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Bristol Appoints AstraZeneca’s Massacesi As Next CMO

 

Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.

Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up

 

Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By 

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

More from Business

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Roche Keen To Cut Out The Middle Men On US Pricing

 
• By 

The Swiss giant has been talking to the US government about selling medicines directly to patients.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.